10-Q: Hestia Insight Pivots to AI Amidst Significant Revenue Decline and Mounting Losses

Hestia Insight Inc. reported a substantial net loss and zero revenue for the six months ended May 31, 2025, as it strategically shifts focus from legacy vending and charging businesses to AI product development and IP-based consulting, while seeking to raise up to $5 million in capital.

Summary

• Reported zero revenue for the six months ended May 31, 2025, a significant decrease from $1,279,401 in the same period last year.
• Incurred a net loss of $644,757 for the six months ended May 31, 2025, compared to a net income of $1,148,597 in the prior year period.
• Experienced an operating loss of $232,907 for the six months ended May 31, 2025, a reversal from an operating income of $1,114,974 in the previous year.
• Discontinued legacy operations in Healthy Vending Services and Portable Charging Network Business.
• Strategically shifted focus to high-growth areas in AI product development and IP-based consulting.
• The Board approved a capital raise of up to $5 million through equity and/or convertible debt to support AI expansion, R&D, and marketing.
• Cash and cash equivalents decreased to $34,332 as of May 31, 2025, from $41,163 as of November 30, 2024.
• Total liabilities increased to $299,709 as of May 31, 2025, from $206,306 as of November 30, 2024.
• Accumulated deficit grew to $759,080 as of May 31, 2025, from $114,323 as of November 30, 2024.
• Management concluded that disclosure controls and procedures were ineffective as of May 31, 2025, due to limited resources and employees.

Sentiment

Score: 2

Explanation: The company reported zero revenue and a significant net loss, indicating severe operational challenges. While a strategic pivot to AI and a planned capital raise offer future potential, the current financial state, going concern warning, and ineffective internal controls present substantial immediate risks and negative performance.

Positives

• Strategic shift towards high-growth areas of AI product development and IP-based consulting.
• Board approval for a capital raise of up to $5 million to fund new strategic initiatives.
• Management team is experienced in risk management and exit planning, and has a global business network in healthcare and finance.

Negatives

• Zero revenue reported for the six months ended May 31, 2025, a substantial decline from $1,279,401 in the prior year period.
• Shift from a net income of $1,148,597 to a net loss of $644,757 year-over-year.
• Significant unrealized loss on equity investments of $387,417 for the six months ended May 31, 2025.
• Accumulated deficit increased to $759,080 as of May 31, 2025.
• Cash and cash equivalents are low at $34,332, insufficient to cover operating expenses for the next twelve months.
• Increased reliance on related party loans, with notes payable to related parties totaling $128,931 as of May 31, 2025.
• Uncertainty regarding the collection of a $48,000 receivable from Aqua Medical due to liquidity concerns.
• Disclosure controls and procedures were deemed ineffective due to limited resources and employees.

Risks

• Going Concern Risk: The company has not established an ongoing source of revenues sufficient to cover operating costs and is dependent on debt and equity financing, raising substantial doubt about its ability to continue as a going concern.
• Capital Raise Uncertainty: There is no assurance that additional equity capital will be raised or that it will be available on satisfactory terms and conditions.
• Revenue Generation Risk: The company's ability to continue as a going concern is dependent on achieving profitable operations and generating significant revenues.
• Intellectual Property Protection: The company owns no patents and relies on trade secrets, trademarks, and contractual safeguards, posing a risk to adequately protecting its intellectual property rights.
• Competition: The company faces competition from various advisory firms and direct service providers in its consulting business and future ventures.
• Regulatory Compliance: The healthcare industry is highly regulated, and failure to anticipate or comply with changing laws and regulations could create liabilities and negatively affect the business.
• Internal Control Weaknesses: Disclosure controls and procedures were deemed ineffective due to limited resources and employees, increasing the risk of financial reporting errors.
• Market Volatility: The trading price of common stock and a downturn in equity and debt markets could make it more difficult to obtain financing.
• Dilution Risk: Future equity or debt issuances for capital raising may result in additional dilution for existing stockholders or new securities with senior rights.

Future Outlook

The company intends to pursue the acquisition and development of healthcare-related technologies in the healthcare and biotech sectors through acquisition, licensing, or joint ventures, with a new strategic focus on AI product development and IP-based consulting. Management is making efforts to raise additional funding to support operations and achieve profitable operations, with a board-approved capital raise of up to $5 million planned.

Management Comments

• Management is making efforts to raise additional funding until a registration statement relating to an equity funding facility is in effect.
• While management believes it will be successful in its capital formation and planned operating activities, there can be no assurance that additional equity capital will be raised or that it will be successful in the development and commercialization of the investments and services it develops or enters into collaboration agreements thereon.
• Ultimately, the Company will need to achieve profitable operations in order to continue as a going concern.
• The Company is positioned to make strategic acquisitions of and enter joint ventures with emerging growth companies with unique sciences and technologies.
• Based on current plans and assumptions, available cash will be insufficient to satisfy cash requirements under present operating expectations.
• The Company will need to raise significant additional capital to fund operations and to provide working capital for ongoing operations and obligations. Therefore, future operation is dependent on the ability to secure additional financing.
• To date, the alternative of ceasing operations has not been considered, nor is it viewed as a likely occurrence.
• Because of the Company's limited resources and limited number of employees, disclosure controls and procedures were concluded to be ineffective as of May 31, 2025.

Industry Context

Hestia Insight's pivot to AI product development and IP-based consulting aligns with a broader industry trend of digital transformation and the increasing integration of artificial intelligence across various sectors, including healthcare and biotech. This shift positions the company to potentially capitalize on emerging technological advancements, moving away from less scalable physical vending and charging businesses. However, entering the competitive AI and IP consulting space requires significant capital and expertise, which the company is currently seeking to acquire.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings that would have a material adverse effect on its business, operating results, financial condition, or cash flows.

Related Party Transactions

• On January 15, 2024, the company entered into a $50,000 note payable to ECL Capital Partners Corp, extended until January 15, 2026, with 6.00% interest per annum.
• On August 25, 2024, the company entered into a $25,000 note payable to ECL Capital Partners Corp, due August 24, 2025, with 6.00% interest per annum.
• On February 17, 2025, the company entered into a $25,000 note payable to ECL Capital Partners Corp, due February 17, 2026, with 6.00% interest per annum.
• On March 17, 2025, the company entered into a $25,000 note payable to ECL Capital Partners Corp, due March 17, 2026, with 6.00% interest per annum.
• An additional short-term loan of $3,931 was received from Mr. Edward C. Lee (Chairman) in May 2024, bearing no interest.
• Accrued interest, related party, increased from $3,038 (November 30, 2024) to $5,331 (May 31, 2025).
• Notes Payable, related party, increased from $78,931 (November 30, 2024) to $128,931 (May 31, 2025).

Stakeholder Impact

• Shareholders: Face significant dilution risk from the planned equity capital raise and potential loss of investment due to the going concern warning and current operational losses. The stock options granted to management also represent potential future dilution.
• Creditors: Existing creditors, particularly related parties, face increased risk given the company's going concern status and reliance on further financing.
• Employees: The company has only three employees, and its reliance on independent contractors suggests a lean structure, but the going concern risk impacts job security.
• Customers: The discontinuation of vending and charging businesses means existing customers for those services will no longer be served. New customers for AI/IP consulting are yet to be established.

Next Steps

• Raise additional funding through equity and/or convertible debt (up to $5 million).
• Expand the AI development team.
• Accelerate R&D in AI product development.
• Market AI consulting tools.
• Pursue strategic acquisitions, licensing, or joint ventures in healthcare and biotech sectors, particularly for emerging growth companies with unique sciences and technologies.
• Monitor the Aqua Medical receivable for potential collection.
• Address and improve disclosure controls and procedures.

Key Dates

Recommendation

Hestia Insight Inc. presents an extremely high-risk investment profile. The company reported zero revenue and a substantial net loss for the latest six-month period, a dramatic reversal from prior year profitability. It explicitly carries a 'going concern' warning, indicating severe doubts about its ability to continue operations without significant external funding. While the strategic pivot to AI and IP consulting is a positive directional shift, it is currently unfunded and speculative, with no guarantee of successful execution or market penetration. The company's cash position is critically low, and its disclosure controls are deemed ineffective. The reliance on related-party debt and the potential for significant shareholder dilution from a future capital raise further compound the risks. Given the dire financial performance, the going concern warning, and the highly speculative nature of its new business model, a seasoned investor would likely recommend a 'strong sell' to avoid further capital erosion.

Keywords

Hestia Insight, SEC Filing, 10-Q, Quarterly Report, Financial Results, Net Loss, Revenue Decline, Strategic Shift, AI Development, IP Consulting, Capital Raise, Going Concern, Related Party Debt, Healthcare Sector, Biotech Sector, Corporate Governance, Internal Controls, Equity Investments